Abstract
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
Keywords: Targeted alpha therapy, alpha emitter, production, uranium-230, thorium-227, thorium-226, actinium-225, radium- 223, bismuth-213, lead-212
Current Radiopharmaceuticals
Title: Production of Alpha Emitters for Targeted Alpha Therapy
Volume: 1 Issue: 3
Author(s): A. Morgenstern, K. Abbas, F. Bruchertseifer and C. Apostolidis
Affiliation:
Keywords: Targeted alpha therapy, alpha emitter, production, uranium-230, thorium-227, thorium-226, actinium-225, radium- 223, bismuth-213, lead-212
Abstract: Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
Export Options
About this article
Cite this article as:
Morgenstern A., Abbas K., Bruchertseifer F. and Apostolidis C., Production of Alpha Emitters for Targeted Alpha Therapy, Current Radiopharmaceuticals 2008; 1 (3) . https://dx.doi.org/10.2174/1874471010801030135
DOI https://dx.doi.org/10.2174/1874471010801030135 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Synergistic Effect of Immunotherapy and Chemotherapy in Cancers: Perspective in High Grade Glioma Treatment
Letters in Drug Design & Discovery Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Current Drug Targets Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates
Medicinal Chemistry Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Subject Index To Volume 7
Current Pharmaceutical Biotechnology